Abstract
The treatment landscape for metastatic renal cell carcinoma has constantly been in flux. In 2005, with the advent of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy, the standard of care shifted to agents such as sunitinib and pazopanib. However, more recently there have been datasets, suggesting that next-generation TKIs such as cabozantinib may play an important role in therapy. Furthermore, immunotherapy has had resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356:125–134
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356:115–124
Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med 369:722–731
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol: Official J Am Soc Clin Oncol 28:1061–1068
Rini BI, Escudier B, Tomczak P, et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England) 378:1931–1939
Escudier B, Pluzanska A, Koralewski P, et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (London, England) 370:2103–2111
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 356:2271–2281
Motzer RJ, Escudier B, Oudard S, et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (London, England) 372:449–456
Atzpodien J, Kirchner H, Jonas U et al (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol: Official J Am Soc Clin Oncol 22:1188–1194
Pal SK, Bergerot P, Figlin RA (2015) Renal cell carcinoma: An update for the practicing urologist. Asian J Urol 2:19–25
Choueiri TK, Motzer RJ (2017) Systemic therapy for metastatic renal-cell carcinoma. New Engl J Med 376:354–366
Singh P, Agarwal N, Pal SK (2015) Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol 16:316
McDermott DF (2011) Immunotherapy and targeted therapy combinations in renal cancer. Current Clin Pharmacool 6:207–213
Albouy B, Gross Goupil M, Escudier B, Massard C (2010) Renal cell carcinoma management and therapies in 2010. Bull Cancer 97:17–28
Ho TH, Choueiri TK, Wang K et al (2016) Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. Eur Urol Focus 2:204–209
Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49
Pal SK, Signorovitch JE, Li N et al (2017) Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. Int J Urol: Official J Jpn Urol Assoc 24:272–278
Hammers HJ, Plimack ER, Sternberg C, et al (2015) CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 33:TPS4578–TPS
Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Official J Am Soc Clin Oncol 27:5794–5799
Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S, Neiman V, Porta C, Choueiri TK, Powles T, Donskov F, Salman P, Kollmannsberger CK, Rini B, Mekan S, McHenry MB, Wind‐Rotolo M, Hammers HJ, Escudier B (2017) Nivolumab + Ipilimumab (N + I) versus Sunitinib (S) for treatment‐naïve advanced or metastatic renal cell carcinoma (aRCC): results from CheckMate 214, including overall survival by subgroups. SITC 2017 ANNUAL MEETING ABSTRACTS BOOK. Maryland: Society for Immunotherapy of Cancer p 103
Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Engl J Med 373:1814–1823
Choueiri TK, Halabi S, Sanford BL et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35:591–597
Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917–927
NIH U.S. National library of medicine https://clinicaltrials.gov/ Accessed January 10, 2018
Choueiri TK, Rini BI, Larkin JMG, et al (2017) Avelumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). J Clin Oncol 35:TPS4594–TPS
Atkins MB, Gupta S, Choueiri TK et al (2015) Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma. J Immuno Ther Cancer 3:353
Lee CVM, Rasco D, Taylor M, Dutcus C, Shumaker R., Schmidt EV, Stepan D., Li D, Motzer RJ (2017) Anti-Cancer Agents & Biologic Therapy Renal Cell Cancer Cancer Immunology and Immunotherapy Genitourinary Cancers. ESMO 2017 Congress. Madrid, Spain: Annals of Oncology v295–v329. 10.1093
Hahn AW, Gill DM, Maughan B et al (2017) Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8:33614–33620
Becerra MF, Reznik E, Redzematovic A, et al (2017) Comparative genomic profiling of matched primary and metastatic tumors in renal cell carcinoma. Eur Urol Focus
Acknowledgements
None.
Conflict of Interest SKP declares consulting agreements with Genentech, Roche, Exelixis, BMS, Ipsen, Novartis, Astellas, Eisai and Pfizer.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bergerot, P., Burns, K., Prajapati, D., Fox, R., Salgia, M., Pal, S.K. (2018). Advances in the Treatment of Metastatic Renal Cell Carcinoma. In: Daneshmand, S., Chan, K. (eds) Genitourinary Cancers . Cancer Treatment and Research, vol 175. Springer, Cham. https://doi.org/10.1007/978-3-319-93339-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-93339-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93338-2
Online ISBN: 978-3-319-93339-9
eBook Packages: MedicineMedicine (R0)